Compare FNF & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNF | ARWR |
|---|---|---|
| Founded | 1847 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 12.4B |
| IPO Year | 2005 | 2009 |
| Metric | FNF | ARWR |
|---|---|---|
| Price | $46.29 | $84.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $60.50 | ★ $83.40 |
| AVG Volume (30 Days) | ★ 1.5M | 1.0M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ 1.98 | N/A |
| Revenue | ★ $14,445,000,000.00 | $16,142,321.00 |
| Revenue This Year | $10.90 | N/A |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | $23.94 | ★ N/A |
| Revenue Growth | ★ 5.58 | N/A |
| 52 Week Low | $42.78 | $27.10 |
| 52 Week High | $60.97 | $95.49 |
| Indicator | FNF | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 50.00 |
| Support Level | $46.93 | $82.70 |
| Resistance Level | $48.89 | $89.67 |
| Average True Range (ATR) | 0.83 | 2.64 |
| MACD | -0.10 | -0.65 |
| Stochastic Oscillator | 41.21 | 51.90 |
Fidelity National Financial Inc is a provider of (i) title insurance, escrow and other title-related services, including trust activities, trustee sales guarantees, recordings and reconveyances and home warranty and (ii) transaction services to the real estate and mortgage industries. It operates in three segments: Title, F&G, Corporate and Other. The title segment that derives the majority of revenue consists of the operations of title insurance underwriters and related businesses, which provide title insurance and escrow and other title-related services including trust activities, trustee sales guarantees, and home warranty products. All of the company's revenue is generated in the United States.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.